J
Jordi Castellsague
Researcher at Pfizer
Publications - 53
Citations - 2822
Jordi Castellsague is an academic researcher from Pfizer. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 23, co-authored 53 publications receiving 2589 citations. Previous affiliations of Jordi Castellsague include Novartis.
Papers
More filters
Journal ArticleDOI
Hormone replacement therapy and risk of venous thromboembolism: population based case-control study
TL;DR: Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use.
Journal ArticleDOI
Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.
TL;DR: NSAID users had a 3-fold greater risk for developing a first-ever diagnosis of clinical ARF compared with non-NSAIDs users in the general population, and NSAIDs should be used with special caution in patients with hypertension and/or HF.
Journal ArticleDOI
Individual NSAIDs and Upper Gastrointestinal Complications: A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project)
Jordi Castellsague,Nuria Riera-Guardia,Brian Calingaert,Cristina Varas-Lorenzo,Annie Fourrier-Réglat,Federica Nicotra,Miriam C. J. M. Sturkenboom,Susana Perez-Gutthann +7 more
TL;DR: In this article, the authors conducted a systematic review and meta-analysis of observational studies to provide summary relative risks (RR) of upper GI complications associated with the use of individual NSAIDs, including selective cyclooxygenase-2 inhibitors.
Journal ArticleDOI
Individual NSAIDs and Upper Gastrointestinal Complications
Jordi Castellsague,Nuria Riera-Guardia,Brian Calingaert,Cristina Varas-Lorenzo,Annie Fourrier-Réglat,Federica Nicotra,Miriam C. J. M. Sturkenboom,Susana Perez-Gutthann +7 more
TL;DR: In this paper, the authors conducted a systematic review and meta-analysis of observational studies to provide summary relative risks (RR) of upper GI complications (UGIC) associated with the use of individual NSAIDs, including selective cyclooxygenase-2 inhibitors.
Journal ArticleDOI
Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.
Christianne L. Roumie,Edward F. Mitchel,Patricia S. Gideon,Cristina Varas-Lorenzo,Jordi Castellsague,Marie R. Griffin +5 more
TL;DR: To validate ICD 9 codes with a high positive predictive value (PPV) for incident strokes, Tennessee Medicaid enrollees aged from 50 to 84 years were studied.